TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors. Read more about TERT promoter mutation as a prognostic marker in patients with advanced urothelial carcinoma treated with immune checkpoint inhibitors.
Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy. Read more about Phase II trial of escalating doses of neoadjuvant atezolizumab for patients with non-metastatic urothelial carcinoma ineligible for cisplatin-based neoadjuvant chemotherapy.
Feasibility study of gallium-68 citrate PET as a bone-tropic imaging biomarker in mCRPC. Read more about Feasibility study of gallium-68 citrate PET as a bone-tropic imaging biomarker in mCRPC.
Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer. Read more about Streamlining the genetics pipeline to increase testing for patients at risk for hereditary prostate cancer.
Implementation of clinician-facing prostate cancer therapeutic clinical trial decision tool at a comprehensive cancer center. Read more about Implementation of clinician-facing prostate cancer therapeutic clinical trial decision tool at a comprehensive cancer center.
INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy. Read more about INNOVATE (NRG-GU008): A randomized phase III trial of salvage radiotherapy and androgen deprivation therapy (ADT) with/without abiraterone and apalutamide for patients with node-positive prostate cancer after radical prostatectomy.
Assessing the impact of the COVID-19 pandemic on patients with genitourinary malignancies. Read more about Assessing the impact of the COVID-19 pandemic on patients with genitourinary malignancies.
Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study. Read more about Androgen deprivation therapy and risk of SARS-CoV-2 infection in men with prostate cancer: A University of California (UC) Health System registry study.
Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis. Read more about Phase II study of pembrolizumab plus capecitabine and bevacizumab in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Interim analysis.
Utilization of a multisite financial reimbursement program to promote racial/ethnic diversity and inclusion in therapeutic cancer clinical trials: The iMPACT Study. Read more about Utilization of a multisite financial reimbursement program to promote racial/ethnic diversity and inclusion in therapeutic cancer clinical trials: The iMPACT Study.
